SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance,
which has already been approved as a pharmaceutical product of similar indication.